IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Graham Nigel Maw, et al. :

APPLICATION NO.: Not Yet Assigned

: Examiner:

FILING DATE: Herewith

: Group Art Unit:

TITLE: Compounds for the Treatment of Female Sexual:

•

Dysfunction

Hon. Commissioner for Patents

Washington, D.C. 20231

Sir

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s). The references for this application can be found in the parent case U.S. Non-Provisional Application No. 09/708.392.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: October 15 200 3

Arlene K. Musser Attorney for Applicant(s)

Reg. No. 37,895

Pfizer Inc.

Patent Department, MS 8260-1611 Fastern Point Road

Groton, Connecticut 06340

(860) 715-0871

EXPRESS MAIL NO. EV 38059916 US-

INFOF	RMAT	ION DIS	SCLOS	URE CIT	TATION	АТ	TY. DOC	KET N	D. PC1034	43C	SER	IAL NO.	.Not Yet A	ssign	ed
(L	Jse se	veral si	heets if	necessa	ary)	AF	PLICANT	Gr.	aham Nige	el Maw, et al.					
						FII	ING DAT	E Her	ewith		GRO	UP			
						U.5	S. PATEN	T DOC	UMENTS						
EXAMINER INITIAL				000	UMENT NUN	IBER			OATE	NAME		CLASS	SUBCLASS	FILING IF APPRI	DATE OPRIATE
7S.K./	US	4	6	6	6	9	0	8	5/19/87	Hamilton		514	229		
	us	5	5	7	4	0	6	8	11/12/96	Stamler, et	al.	514	562		
7S.K.7	us	5	9	8	1	5	2	7	11/9/99	Daugan, et	al.	514	290		
/S.K./	υs	5	8	6	1	3	9	6	1/19/99	Niewohner, e	t al.	514	234.2		
75.K./	us	5	6	1	2	3	1	4	3/18/97	Stamler, et	al.	514	13		
7S.K./	us	6	0		3	2	5	2	3/28/00	Bombrun		514	292		
/S.K./	us	6		۰	4	•	5	2	9/25/01	Place, et a	l.	514	302		
/S.K./	us	6	3	3	6	4	5	2	11/13/01	Garvey, et :	al.	514	263		
/S.K./	us	6		0	6	в	4	1	10/23/01	Place, et a		514	149		
						_		ENT D	OCUMEN.						
			DO	CUMENT NU	MBER				DATE	COUNTRY		CLASS	SUBCLASS	TRANS	LATION
														YES	NO
/S.K./	EP	9	9		2	•		3_	4/24/99	European		C07D	487/04		
/S.K./	EP	2	4	4	1	4	2		7/5/97	European		C07D	473/00		
/S.K./	EP	9	2	9	4	4	,	4	7/13/88	European		C07D	409/06		
/S.K./	wo	9	1	2	4	9	4	2	4/4/91	Internation	al	A61K	37/02		
/S.K./	wo	9	2	2	9	9	2		6/12/97	Internation	al	C07D	239/95		
/S.K./	wo	2	4	3		9	2	•	10/2/97	Internation	al	C12N	15/55		
/S.K./	wo	2	4	3	9	2	2	0	10/30/97	Internation	al	A61K	33/26		
/S.K./	wo	2	9	2	,	4	2	2	1/29/98	Internation	al	C07D	295/18		
/S.K./	wo	9	9	2	9	2	9		1/29/98	Internation	al	A61K	31/19		
/S.K./	wo	9	5	2	1	5		2	5/6/99	Internation	al	A61K	31/557		
/S.K./	wo	9	9	2	2	7	3	1	5/14/99	Internationa		A61K	31/44		-
/S.K./	wo	0	0	1	5	6	3	9	3/23/00	Internation		C07D	471/04		
/S.K./	wo	0	0	1	5	2	2	8	3/23/00	Internation		A61K	31/4985		
			отн	ER DOC	UMEN	rs (In	cluding A	uthor, 1		Pertinent Pa	_				
/S.K./		Traish	n, A., Mon	eland, R. I	3., Huang	, Y., et	al., Mol. Cel	l Biol. Re	s. Comm., 2,	, 131-137 (1999)					

INFORMA	ATION DISCLOSURE CITATION	ATTY, DOCKET NO. PC10343C	SERIAL NO.Not Yet Assigned
(Use	several sheets if necessary)	APPLICANT Graham Nigel Maw, e	at al.
		FILING DATE Herewith	GROUP
/S.K./	Palle, Bredkjaer, Ottesen and Fahrer	nkrug 1990 Clinical and Experimental Pharmacolo	gy and Physiology vol 17, 61-68.
/S.K./	Beavo JA and Reifsnyder DH, Trend	s Pharmacol. Sci, 11:150 (1990).	
	Wieshaar RE et al., J. Med. Chem., 2	28, 537 (1985).	
/S.K./	Giembycz MA, Biochem. Pharm., 43:	2041 (1992).	
/S.K.	Lowe JA and Cheng JB, Drugs for th	e Future. 17. 799-807 (1992).	
/S.K./		S., et al., "SNV, a lipophilic superactive VIP and	alog, acts through cGMP to promote neuronal
/S.K./	Berman, J.R., Berman, L. & Golds options," <i>Urology</i> , 54 , 385-391 (1999)	stein, I., *Female sexual dysfunction: Incidence.).	, pathophysiology, evaluation, and treatment
/S.K./		et al., "Double blind placebo controlled study v le sexual response," J. Urol., 161, 805 (1999)	with crossover to assess effect of slidenafil on
/S.K./	Burnett, A, Calvin, D., Silver, R. et al 158, 75-78 (1997).	!. "Immunohistochemical description of nitric oxide	e synthase isoforms in human clitoris," J. Urol.,
/S.K./	Diagnostic and statistical manual of r	mental disorders-IV, American Psychiatric Associa	ation: Washington, DC., pp. 493-518 (1987).
/S.K.	Fan, Y.P., Chakder, S & Ratton, S relaxation by vasoactive intestinal po	., "Inhibitory effect of zinc protoporphyrin IX on lypeptide and other receptor agonists," J. Pharma	lower esophageal sphincter smooth muscle acol. Exp. Ther., 285, 468-474 (1998).
/S.K./		A. et al., "Pituitary adenylate cyclase-activating axant activity," Peptides, 16, 1057-1061 (1995).	g peptide (PACAP), a VIP-like peptide, has
/S.K./	Frank, E., Anderson, C. & Rubinstei (1978).	in, D. "Frequency of sexual dysfunction in "norm	nal" couples," N. Engl. J. Med., 229, 111-115
/S.K./	Goldstein, I. & Berman, J.R. "Vasc syndromes," Int. J. Impot. Res., 10, S	zulogenic female sexual dysfunction: vaginal er 84-S90 (1998).	ngorgement and clitoral erectile insufficiency
/S.K.	Gu, Z.F., Jensen, R.T. & Maton, P. agonists and neuropeptides,". Am J.	N. "A primary role for protein kinase A in smo Physiol., 263, G360-G364 (1992).	oth muscle relaxation induced by adrenergic
/S.K./	Hauser-Kronberger, C., Cheung, A.,	Hacker, G. et al., "Peptidergic innervation of the h	uman clitoris," Peptides, 20, 539-543 (1999).
/S.K./	Hoyle, C.H.V., Stones, R.W., Robson neuropeptide containing nerves," J. A	n, T. et al., "Innervation of vasculature and micro Inat., 188, 633-644 (1996).	vasculature of the human vagina by NOS and
/S.K.	Ingenhoven, N. & Beck-Sickinger, expressing NPY receptor subtypes,	A.G. "Flourescent labelled analogues of neur J. Recept. Signal Transduct. Res., 17, 407-418 (1	opeptide Y for the characterisation of cells 997).
/S.K.		I. et al., "Predominant role for nitric oxide in the Mol. Human Reprod., 4, 71-76 (1998).	ne relaxation induced by vasoactive intestinal
/S.K.	Kaplan, S.A., Reis, R.B., Kohm, I.J. Urology, 53, 481-486 (1999).	et al., "Safety and efficacy of sildenafil in postr	menopausal women with sexual dysfunction,"
/S.K.	Kim, Y.C., Choi, H.K., Ahn, Y.S., et contractility," J. Androl., 15, 392-397	 The effect of vasoactive intestinal polypeptis (1994). 	de (VIP) on rabbit cavernosal smooth muscle
/S.K./	Laan, E. & Everaerd, W. "Physiologic	al measures of vaginal vasocongestion,*. Int. J. In	npot. Res., 10, S107-S110 (1998).
7S.K.	Leiblum, S.R. "Definition and classific	ation of female sexual disorders," Int. J. Impotence	ce Res., 10, S104-S106 (1998).

INIT OF THE	TION DIOCI COURT OF ATTOM	ATTY, DOCKET NO. PC10343C	SERIAL NO.Not Yet Assigned
	TION DISCLOSURE CITATION		
(Use	several sheets if necessary)	APPLICANT Graham Nigel Maw, et	
/S.KI/ I	Levin R.J. "The physiology of sexua	FILING DATE Herewith I function in women," Clin. Obstet. Gynecol., 7, 21	GROUP 3-252 (1980).
70.10			
/S.K./	Levin, R.J., "VIP, vagina, clitoral an (1991).	d preurethral glans.: An update on female genita	al arousal," Exp. Clin. Endocrinol., 98, 61-69
/S.K./		nan female sexual arousal," Ann. Rev. Sex Res., 3	• • •
/S.K./	Levin, R.J., & Wagner, G.) "TRH and (1986	vaginal blood flow-effects in conscious women ar	nd anaesthetized sheep," J. Physiol., 378, 83F
/S.K./	Lundberg, J.M., Modin, A. & Malmstr Sci., 17, 301-304 (1996).	om, R.E. *Recent developments with neuropeptide	e Y receptor antagonists,* Trends. Pharmacol.
/S.K./	Ottesen, B., Gerstenberg, T. Ulrichs smooth muscle activity in women,* E	en, H. et al., "Vasoactive intestinal oplypeptide (vur. J. Clin. Invest., 13, 321-324 (1983).	/IP) increases vaginal blood flow and inhibits
/S.K./	Ottesen, B., Wagner, G & Fahreni Pharmacological and Endocrinology pp 66-97. (1988).	krug, J., Peptide Innervation of the sexual orga of Sexual Function, Sitsen, J.M.A. (eds), Amster	ins. In: Handbook of Sexology, Vol. 6, The dam: Elsevier Science Publishers, chapter 4.
/S.K.	Ottensen, B. Pedersen, B., Nielsen, 8, 797-800 (1987).	J. et al., "Vasoactive polypeptide (VIP) provokes va	aginal lubrication in normal women," Peptides
/S.K/	Park, K., Goldstein, I., Andry, C., et a insufficiency and clitoral erectile insu	al.,. "Vasculogenic female sexual dysfunction: The fficiency," Int. J. Impotence Res., 9, 27-37 (1997).	hemodynamic basis for vaginal engorgement
/S.K./	Rosen, R. Taylor, J., Leiblum, S. e outpatient gynecological clinic, "J. Se	of al., "Prevalence of sexual dysfunction in women ox Marital Ther., 19, 171-188 (1993).	en: results of a survey of 329 women in ar
/S.K./	Schlavi, R.C. & Seagraves, R.T., "Th	e biology of sexual function," Psychiat. Clin. North	. Am., 18, 7-23 (1995).
/S.K./	Schoeffter, P. & Stoclet, J.C., "Effer aorta," Eur. J. Pharmacol., 109, 275-	ct of vasoactive intestinal polypeptide (VIP) on c 279 (1985).	yclic AMP level and relaxation in rat isolated
/S.K./	Serradell-Le Gal, C., Valette, G., F antagonist, "FEBS Letters, 3, 192-19	Rouby, P.E. et al., "SR 120819A, an orally-active (1995).	ve and selective neuropeptide Y Y1 recpto
/S.K./	Sjoberg, I. "The vagina: Morphologic	al, functional and ecological aspects," Acta Obst. C	Synecol. Scand., 71, 84-85 (1992).
/S.K./	Spector, I.P. & Carey, M.P. "Incidence Behav., 19, 389-408 (1990).	ce and prevalence of sexual dysfunctions: a critica	I review of the empirical literature," Arch. Sex.
/S.K.	Wagner, G. "Aspects of genital physi	ology and pathology," Sem. Neurol., 12, 87-97 (19	92).
/S.K./	Werbin, T., Salimpour, P., Berman, stimulation," J. Urol., 161, 688 (1999)	L., et al., "Effect of sexual stimulation and age).	on genital blood flow in women and sexual
/S.K.,	Wincze, J.P., Albert, a. & Bansal, S. 22, 587-601 (1993).	"Sexual arousal in diabetic females: Physiological	and self-report measures," Arch. Sex Behav.
/S.K./	Wieland, H.A., Willim, K.D., Entzerol BIBP 3226," J Pharmacol Exp Ther.,	h, M. et al., "Subtype selectivity and antagonist pr 275, 143-9 (1995).	ofile of the nonpeptide Y1 receptor antagonis
/S.K./	Ottesen, B. American Journal of Obs Genital Tract*, Volume 147, pages 2	tetrics & Gynecology, "Vasoactive Intestinal Peptic 08-224 (1983)	de as a Neurotransmitter in the Female
/S.K./	Clark, J.T., et al., <u>Endocrinology</u> , *Ne pages 2435-2442 (1985)	europeptide Y Stimulates Feeing But Inhibits Sexua	al Behavior in Rats", Volume 117, No. 6.,
/S.K./	Suzuki, H., et al., American Journal of Cheek Pouch Vessels in Situ", Volun	of Physiology, *Neutral Endopeptridase Modulates ne 271, No. 2, Part. 2, pages R393-R397 (1996)	VIP-induced Vasodilalation In Hamster
/S.K./	Erdos, E.G., et al., <u>Laboratory Invest</u> 737-747 (1985)	igation, "Neutral Metalloendopeptidase In Human I	Male Genital Tract", Volume 52, No. 4, pages

INFORMA	TION DISCLOSURE CITATION	ATTY, DOCKET NO. PC10343C	SERIAL NO.Not Yet Assigned
(Use s	several sheets if necessary)	APPLICANT Graham Nigel Maw,	et al.
		FILING DATE Herewith	GROUP
S.K./	United States Non-Provisional Patent Treatment of Female Sexual Dysfund	t Application No. 09/708,344, filed November 8, tion", (Our Docket No. PC10931A)	2000; Maw, et al., *Compounds for the
S.K./	United States Non-Provisional Patent Treatment of Female Sexual Dysfund	t Application No. 09/708,365, filed November 8, ction*, (Our Docket No. PC10932A)	2000; Maw, et al., *Compounds for the
/S.K.	United States Non-Provisional Patent Treatment of Female Sexual Dysfund	t Application No. 09/708,393, filed November 8,	2000; Maw, et al., "Compounds for the
'S.K./	Hedlund, et al., <u>PNASu</u> , "Erectile Dys 2354 (2000)	sfunction in Cyclin GMP-Dependent Kinase I-De	eficient Mice*, Volume 97, No. 5, pages 2349-
	U.S. 2002-0052370, filed April 02; Ba	arber, et al., 514/237.5	
1 1			
S.K./ S.K./	U.S. 2002-0052370, filed April 02; Ba U.S. 2002-0169101, filed November 3		
S.K./	U.S. 2002-0169101, filed November		
S.K./	U.S. 2002-0169101, filed November: US 2002/0028846		

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE